Diabetes, Vol 47, Issue 9 1512-1518, Copyright © 1998 by American Diabetes Association

ARTICLES

Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin

JW Fischer, C Tschope, A Reinecke, CM Giachelli and T Unger
Department of Pathology, University of Washington School of Medicine, Seattle, USA. jensf@u.washington.edu

The model of streptozotocin (STZ)-induced diabetes in Wistar rats was used to study the expression of osteopontin during development of diabetic nephropathy. Diabetes was confirmed by serum glucose levels exceeding 16 mmol/l during the experimental period of 12 weeks. During this period of time, diabetic nephropathy developed, as characterized by a reduced glomerular filtration rate (2.7 +/- 0.3 ml/min in controls vs. 1.7 +/- 0.1 ml/min in diabetic rats) and proteinuria (8.3 +/- 1.7 mg/24 h in controls vs. 22.0 +/- 4 mg/24 h in diabetic rats). Northern blot analysis revealed a time-dependent upregulation of renal cortical osteopontin expression reaching 138 +/- 6% of control levels after 2 weeks and 290 +/- 30% (mean +/- SE, n = 6-9) after 12 weeks. By immunostaining, the increased osteopontin expression could be located to the tubular epithelium of the renal cortex. Chronic treatment of animals with ramipril (3 mg/kg) during the 12-week experimental period led to a further increase in osteopontin mRNA expression in diabetic animals, amounting to 570 +/- 73% (mean +/- SE, n = 6) of controls. Increased levels of osteopontin were not associated with accumulation of monocyte/macrophages that were identified by the cell type specific monoclonal antibody ED-1. The increased osteopontin expression in ramipril-pretreated rats was abolished by application of the bradykinin B2-receptor antagonist, icatibant (0.5 mg/kg). In addition, increased osteopontin expression in diabetic rats, which did not receive any treatment after STZ injection, could as well be reduced by icatibant given for the final 2 weeks of the experimental period. These data suggest that a strong bradykinin B2-receptor-mediated upregulation of osteopontin occurs during the pathogenesis of experimental diabetic nephropathy in rats.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Scatena, L. Liaw, and C. M. Giachelli Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2302 - 2309. [Abstract] [Full Text] [PDF]

				C. Guo, D. Martinez-Vasquez, G. P. Mendez, M. F. Toniolo, T. M. Yao, E. M. Oestreicher, T. Kikuchi, N. Lapointe, L. Pojoga, G. H. Williams, et al. Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus Endocrinology, November 1, 2006; 147(11): 5363 - 5373. [Abstract] [Full Text] [PDF]

				R. Mathew, S. Futterweit, E. Valderrama, A. A. Tarectecan, J. E. Bylander, J. S. Bond, and H. Trachtman Meprin-{alpha} in chronic diabetic nephropathy: interaction with the renin-angiotensin axis Am J Physiol Renal Physiol, October 1, 2005; 289(4): F911 - F921. [Abstract] [Full Text] [PDF]

				A. Sahai, P. Malladi, X. Pan, R. Paul, H. Melin-Aldana, R. M. Green, and P. F. Whitington Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin Am J Physiol Gastrointest Liver Physiol, November 1, 2004; 287(5): G1035 - G1043. [Abstract] [Full Text] [PDF]

				A. Sahai, P. Malladi, H. Melin-Aldana, R. M. Green, and P. F. Whitington Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G264 - G273. [Abstract] [Full Text] [PDF]

				K. Susztak, E. Bottinger, A. Novetsky, D. Liang, Y. Zhu, E. Ciccone, D. Wu, S. Dunn, P. McCue, and K. Sharma Molecular Profiling of Diabetic Mouse Kidney Reveals Novel Genes Linked to Glomerular Disease Diabetes, March 1, 2004; 53(3): 784 - 794. [Abstract] [Full Text] [PDF]

				D. J. Kelly, J. L. Wilkinson-Berka, S. D. Ricardo, A. J. Cox, and R. E. Gilbert Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats Nephrol. Dial. Transplant., June 1, 2002; 17(6): 985 - 991. [Abstract] [Full Text] [PDF]

				A. Verhulst, V. P. Persy, A. R. Van Rompay, W. A. Verstrepen, M. F. Helbert, and M. E. De Broe Osteopontin Synthesis and Localization along the Human Nephron J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1210 - 1218. [Abstract] [Full Text] [PDF]

				C. P. Sodhi, S. A. Phadke, D. Batlle, and A. Sahai Hypoxia Stimulates Osteopontin Expression and Proliferation of Cultured Vascular Smooth Muscle Cells: Potentiation by High Glucose Diabetes, June 1, 2001; 50(6): 1482 - 1490. [Abstract] [Full Text]

				C. P. Sodhi, S. A. Phadke, D. Batlle, and A. Sahai Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin Am J Physiol Renal Physiol, April 1, 2001; 280(4): F667 - F674. [Abstract] [Full Text] [PDF]

				M. Takemoto, K. Yokote, M. Nishimura, T. Shigematsu, T. Hasegawa, S. Kon, T. Uede, T. Matsumoto, Y. Saito, and S. Mori Enhanced Expression of Osteopontin in Human Diabetic Artery and Analysis of Its Functional Role in Accelerated Atherogenesis Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 624 - 628. [Abstract] [Full Text] [PDF]